Abstract | OBJECTIVE: METHODS: RESULTS: The recruitment of the polymorphonuclear cells induced by MSU injection into mouse peritoneal cavity was reduced by 35% with γ(3) MSH (1 nmol), whereas administration of a much lower dose of purified latent LAP-MMP-γ(3)MSH (0.03 nmol) attenuated leucocyte influx by 50%. Intramuscular gene delivery of plasmids coding LAP- MMP-VIP and LAP- MMP-αMSH at disease onset reduced the development of CIA compared with LAP- MMP, which does not contain any therapeutic moiety. Histological analysis confirmed a significantly lower degree of inflammation, bone and cartilage erosion in groups treated with LAP- MMP-VIP or LAP- MMP-αMSH. Antibody titres to collagen type II and inflammatory cytokine production were also reduced in these two groups. CONCLUSION:
|
Authors | Sandrine Vessillier, Gill Adams, Trinidad Montero-Melendez, Rita Jones, Michael Seed, Mauro Perretti, Yuti Chernajovsky |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 71
Issue 1
Pg. 143-9
(Jan 2012)
ISSN: 1468-2060 [Electronic] England |
PMID | 21998117
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Cytokines
- Peptide Fragments
- Recombinant Fusion Proteins
- Transforming Growth Factor beta
- Vasoactive Intestinal Peptide
- Melanocyte-Stimulating Hormones
|
Topics |
- Animals
- Anti-Inflammatory Agents, Non-Steroidal
(pharmacokinetics, therapeutic use)
- Arthritis, Experimental
(drug therapy, metabolism, pathology, therapy)
- Cytokines
(blood)
- Drug Delivery Systems
- Drug Design
- Drug Evaluation, Preclinical
(methods)
- Genetic Therapy
(methods)
- Half-Life
- Male
- Melanocyte-Stimulating Hormones
(genetics, pharmacokinetics, therapeutic use)
- Mice
- Mice, Inbred DBA
- Peptide Fragments
(genetics, pharmacokinetics, therapeutic use)
- Peritonitis
(drug therapy, metabolism, therapy)
- Recombinant Fusion Proteins
(pharmacokinetics, therapeutic use)
- Tissue Distribution
- Transforming Growth Factor beta
(therapeutic use)
- Treatment Outcome
- Vasoactive Intestinal Peptide
(genetics, pharmacokinetics, therapeutic use)
|